Effectiveness of entecavir or telbivudine therapy in patients with chronic hepatitis B virus infection following the interferon therapy failure compared with de novo therapy with entecavir and telbivudine.

Trial Profile

Effectiveness of entecavir or telbivudine therapy in patients with chronic hepatitis B virus infection following the interferon therapy failure compared with de novo therapy with entecavir and telbivudine.

Completed
Phase of Trial: Phase II

Latest Information Update: 26 Jul 2017

At a glance

  • Drugs Entecavir (Primary) ; Telbivudine (Primary)
  • Indications Hepatitis B
  • Focus Biomarker; Pharmacodynamics; Therapeutic Use
  • Most Recent Events

    • 26 Jul 2017 New trial record
    • 01 Jun 2017 Results published in the Medicine
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top